BAX-induced cell death may not require interleukin 1β-converting enzyme-like proteases

Por Xiang, Jialing, Chao, Debra T., Korsmeyer, Stanley J.
Publicado em 1996

Functional Characterization of N297A, A Murine Surrogate for low-Fc Binding Anti-Human CD3 Antibodies

Por Chao, Debra T., Ma, Xiaohong, Li, Olga, Park, Hyunjoo, Law, Debbie
Publicado em 2009

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways

Por Balasa, Balaji, Yun, Rui, Belmar, Nicole A., Fox, Melvin, Chao, Debra T., Robbins, Michael D., Starling, Gary C., Rice, Audie G.
Publicado no Cancer Immunol Immunother (2014)

A function blocking anti-mouse integrin α5β1 antibody inhibits angiogenesis and impedes tumor growth in vivo

Por Bhaskar, Vinay, Zhang, Dong, Fox, Melvin, Seto, Pui, Wong, Melanie HL, Wales, Pauline E, Powers, David, Chao, Debra T, DuBridge, Robert B, Ramakrishnan, Vanitha
Publicado em 2007

Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells

Por Ye, Shiming, Fox, Melvin I., Belmar, Nicole A., Sho, Mien, Chao, Debra T., Choi, Donghee, Fang, Yuni, Zhao, Vivian, Keller, Stephen F., Starling, Gary C., Culp, Patricia A.
Publicado no J Immunol Res (2017)

Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR

Por Purcell, James W., Kim, Han K., Tanlimco, Sonia G., Doan, Minhtam, Fox, Melvin, Lambert, Peter, Chao, Debra T., Sho, Mien, Wilson, Keith E., Starling, Gary C., Culp, Patricia A.
Publicado em 2014

Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb

Por Chao, Debra T., Su, Mian, Tanlimco, Sonia, Sho, Mien, Choi, Donghee, Fox, Mel, Ye, Shiming, Hsi, Eric D., Durkin, Lisa, Yin, Johnny, Zhang, Yongke, Kim, Han, Starling, Gary C., Culp, Patricia A.
Publicado em 2012

PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis

Por Woo, Jacky, Vierboom, Michel PM, Kwon, Hakju, Chao, Debra, Ye, Shiming, Li, Jianmin, Lin, Karen, Tang, Irene, Belmar, Nicole A, Hartman, Taymar, Breedveld, Elia, Vexler, Vladimir, ‘t Hart, Bert A, Law, Debbie A, Starling, Gary C
Publicado em 2013

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

Por van Rhee, Frits, Szmania, Susann M., Dillon, Myles, van Abbema, Anne M., Li, Xin, Stone, Mary K., Garg, Tarun K, Shi, JuMei, Moreno-Bost, Amberly M., Yun, Rui, Balasa, Balaji, Ganguly, Bishwa, Chao, Debra, Rice, Audi G., Zhan, Fenghuang, Shaughnessy, John D., Barlogie, Bart, Yaccoby, Shmuel, Afar, Daniel E.H.
Publicado em 2009